WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319523

CAS#: 111974-69-7 (free base)

Description: Quetiapine, marketed as Seroquel, is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder. It is also sometimes used as a sleep aid because of its sedating effect but this use is not recommended. Quetiapine is a dopamine, serotonin, and adrenergic antagonist, and a potent antihistamine with clinically negligible anticholinergic properties. Quetiapine binds strongly to serotonin receptors; the drug acts as partial agonist at 5-HT1A receptors.

Price and Availability


USD 50
USD 150
USD 750
USD 2450

USD 70
USD 250
USD 1250
USD 3950

USD 90
USD 450
USD 1950
Ask price

Quetiapine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 319523
Name: Quetiapine
CAS#: 111974-69-7 (free base)
Chemical Formula: C21H25N3O2S
Exact Mass: 383.16675
Molecular Weight: 383.51
Elemental Analysis: C, 65.77; H, 6.57; N, 10.96; O, 8.34; S, 8.36

Synonym: ICI 204,636; ICI 204636; ICI-204636; ICI204636; quetiapine fumarate; Quetiapine; brand name: Seroquel.

IUPAC/Chemical Name: 2-(2-(4-dibenzo[b,f][1,4]thiazepine- 11-yl- 1-piperazinyl)ethoxy)ethanol


InChi Code: InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Related CAS#
CAS# 111974-72-2 ( Quetiapine hemifumarate)
CAS#111974-69-7 ( Quetiapine free base).


1: Hutton P, Taylor PJ, Mulligan L, Tully S, Moncrieff J. Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal. Br J Psychiatry. 2015 May;206(5):360-70. doi: 10.1192/bjp.bp.114.154377. Review. PubMed PMID: 25934300.

2: Piróg-Balcerzak A, Habrat B, Mierzejewski P. [Misuse and abuse of quetiapine]. Psychiatr Pol. 2015 Jan-Feb;49(1):81-93. doi: 10.12740/PP/32923. Review. Polish. PubMed PMID: 25844412.

3: Styczeń K, Datka W, Jaeschke R, Drozdowicz K, Siwek M, Dudek D. [The place of quetiapine extended release in the treatment of mental disorders]. Psychiatr Pol. 2015 Jan-Feb;49(1):67-80. doi: 10.12740/PP/33909. Review. Polish. PubMed PMID: 25844411.

4: Pringsheim T, Gardner D, Patten SB. Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? BMJ. 2015 Mar 4;350:h569. doi: 10.1136/bmj.h569. Review. PubMed PMID: 25739588.

5: Kreys TJ, Phan SV. A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy. 2015 Feb;35(2):175-88. doi: 10.1002/phar.1529. Review. PubMed PMID: 25689246.

6: Masi G, Milone A, Veltri S, Iuliano R, Pfanner C, Pisano S. Use of quetiapine in children and adolescents. Paediatr Drugs. 2015 Apr;17(2):125-40. doi: 10.1007/s40272-015-0119-3. Review. PubMed PMID: 25686575.

7: Millard HY, Wilson BA, Noordsy DL. Low-dose quetiapine induced or worsened mania in the context of possible undertreatment. J Am Board Fam Med. 2015 Jan-Feb;28(1):154-8. doi: 10.3122/jabfm.2015.01.140105. Review. PubMed PMID: 25567837.

8: Samalin L, Tremey A, Llorca PM. Quetiapine extended release for the treatment of bipolar disorder. Expert Rev Neurother. 2014 Sep;14(9):987-1005. doi: 10.1586/14737175.2014.946407. Epub 2014 Aug 6. Review. PubMed PMID: 25096854.

9: Hasnain M, Vieweg WV, Howland RH, Kogut C, Breden Crouse EL, Koneru JN, Hancox JC, Digby GC, Baranchuk A, Deshmukh A, Pandurangi AK. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. Ther Adv Psychopharmacol. 2014 Jun;4(3):130-8. doi: 10.1177/2045125313510194. Review. PubMed PMID: 25057346; PubMed Central PMCID: PMC4107702.

10: Howland RH. The comparative cardiac effects of haloperidol and quetiapine: parsing a review. J Psychosoc Nurs Ment Health Serv. 2014 Jun;52(6):23-6. doi: 10.3928/02793695-20140515-01. Review. PubMed PMID: 24967672.

11: Liou LS, Hung YJ, Hsieh CH, Hsiao FC. Aggravation of hypertriglyceridemia and acute pancreatitis in a bipolar patient treated with quetiapine. Yonsei Med J. 2014 May;55(3):831-3. doi: 10.3349/ymj.2014.55.3.831. Epub 2014 Apr 1. Review. PubMed PMID: 24719155; PubMed Central PMCID: PMC3990081.

12: Anderson SL, Vande Griend JP. Quetiapine for insomnia: A review of the literature. Am J Health Syst Pharm. 2014 Mar 1;71(5):394-402. doi: 10.2146/ajhp130221. Review. PubMed PMID: 24534594.

13: Vella T, Mifsud J. Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring. J Pharm Pharmacol. 2014 Jun;66(6):747-59. doi: 10.1111/jphp.12209. Epub 2014 Jan 7. Review. PubMed PMID: 24392714.

14: Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013 Nov 18;11:CD006625. doi: 10.1002/14651858.CD006625.pub3. Review. PubMed PMID: 24249315.

15: Weisler R, McIntyre RS, Bauer M. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. Expert Rev Neurother. 2013 Nov;13(11):1183-200. doi: 10.1586/14737175.2013.846519. Review. PubMed PMID: 24175721.

16: Weisler R, McIntyre RS. The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. Expert Rev Neurother. 2013 Nov;13(11):1161-82. doi: 10.1586/14737175.2013.846520. Review. PubMed PMID: 24175720.

17: López-Muñoz F, Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry. 2013 Sep 12;4:102. doi: 10.3389/fpsyt.2013.00102. Review. PubMed PMID: 24062697; PubMed Central PMCID: PMC3770982.

18: Zhornitsky S, Wee Yong V, Koch MW, Mackie A, Potvin S, Patten SB, Metz LM. Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. CNS Neurosci Ther. 2013 Oct;19(10):737-44. doi: 10.1111/cns.12154. Epub 2013 Jul 22. Review. PubMed PMID: 23870612.

19: Carney AC. Efficacy of quetiapine off-label uses: data synthesis. J Psychosoc Nurs Ment Health Serv. 2013 Aug;51(8):11-8. doi: 10.3928/02793695-20130709-01. Epub 2013 Jul 18. Review. PubMed PMID: 23848159.

20: Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013 May 31;5:CD007815. doi: 10.1002/14651858.CD007815.pub2. Review. PubMed PMID: 23728667.